(Q36655179)

15 August 2017

1 reference

title

Calcium channel blockers in the spectrum of antihypertensive agents (English)

1 reference

15 August 2017

Philip R Liebson

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

17

1 reference

15 August 2017

page(s)

2385-2401

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Systolic hypertension in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Treatment of isolated systolic hypertension: the SHELL study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Spinning the risks and benefits of calcium antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

The role of calcium antagonists in stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Management of hypertensive chronic kidney disease: role of calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Antihypertensive therapy: special focus on drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

21 January 2018

Calcium-antagonist drugs

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

Evidence that new antihypertensives are superior to older drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.17.2385

10.1517/14656566.7.17.2385

21 January 2018

Identifiers

DOI

1 reference

release_2wmewzwkh5eirajjebjiiiqooi

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2wmewzwkh5eirajjebjiiiqooi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference